In animal models of heart failure induced by high-frequency pacing, ischaemia, and obesity, GLP-1RAs inhibit left ventricular remodelling and improve left ventricular contractility and diastolic function through anti-inflammatory effects, cardiomyocyte apoptosis inhibition, and glucose metabolism enhancement in cardiomyocytes [38,39,40]
Common red flags include: Claims that a patch can replace prescription GLP-1 medications without medical oversight References to GLP-1 effects without citing human clinical research Proprietary blends that obscure ingredient amounts or mechanisms Claims that the patches contain GLP-1 active ingredients Responsible metabolic health products explain what they support, how they fit into a broader routine, and where their limitations are
Expected Weight Loss Results Clinical trials of semaglutide 2.4 mg injections showed meaningful weight reduction
3B ) and IL-10 (all p 0.017 sex, treatment and diet interaction: F (1,40) = 4.258, p 2 = 0.155, p = 0.046